This Article Figures Only Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Götrick, B. Articles by Tobin, G. Search for Related Content PubMed PubMed Citation Articles by Götrick, B. Articles by Tobin, G. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Hazardous Substances DB PILOCARPINE TRAMADOL HYDROCHLORIDE Medline Plus Health Information Salivary Gland Disorders Social Bookmarking                         What's this?

Oral Pilocarpine for Treatment of Opioid-induced Oral Dryness in Healthy Adults

¹ Department of Hospital Dentistry and
⁴ Hospital Pharmacy, Malmö University Hospital, SE-205 02 Malmö, Sweden;
² Department of Oral Diagnostics and
³ Department of Cariology, Faculty of Odontology, Malmö University, SE-205 06 Malmö, Sweden; and
⁵ Department of Pharmacology, Göteborg University, Box 431, SE-405 30 Göteborg, Sweden;

Correspondence: ^* corresponding author, bengt.gotrick{at}skane.se

Pilocarpine induces a profuse flow of saliva when administered orally, but effects on drug-induced oral dryness have not been examined. The aim of this trial was to investigate if pilocarpine increases production of saliva in individuals suffering from dry mouth due to treatment with opioids. Sixty-five individuals were enrolled in a randomized, double-blind, placebo-controlled trial. The subjects received tramadol (50 mg t.d.s.) to induce oral dryness, and were thereafter assigned to one of three groups. Secretion rate of saliva was measured before and after tramadol, and after the oral administration of pilocarpine (5 mg), placebo, or no treatment. Baseline characteristics did not differ among the groups (mean ± SEM: 0.37 ± 0.06 mL/min), and tramadol lowered the secretion at the same level in all groups (0.15 ± 0.02 mL/min). Pilocarpine increased the flow above that observed with placebo (0.66 ± 0.19 vs. 0.15 ± 0.02 mL/min). Thus, pilocarpine re-establishes the flow of saliva in the state of tramadol-induced oral dryness.

Key Words: pilocarpine • oral dryness • randomized controlled trial • drug-induced xerostomia

Journal of Dental Research, Vol. 83, No. 5, 393-397 (2004)
DOI: 10.1177/154405910408300508


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				J. Nikles, G. Mitchell, J. Walters, J. Hardy, P. Good, D. Rowett, T. Shelby-James, and D. Currow Prioritising drugs for single patient (n-of-1) trials in palliative care Palliative Medicine, October 1, 2009; 23(7): 623 - 634. [Abstract] [PDF]

				K. J. MASTERS Pilocarpine Treatment of Xerostomia Induced by Psychoactive Medications Am J Psychiatry, May 1, 2005; 162(5): 1023 - 1023. [Full Text] [PDF]